Literature DB >> 16862581

Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats.

Bai-Yun Zeng1, Salma Bukhatwa, Atsuko Hikima, Sarah Rose, Peter Jenner.   

Abstract

Systemic administration of proteasomal inhibitors to rats has been proposed as producing progressive nigral dopaminergic cell loss and impairment of motor function, although this has proved difficult to reproduce. We report reproducible loss of tyrosine hydroxylase-positive cells in substantia nigra and decrease in locomotor activity by proteasomal inhibitor injection in rats up to 10 months after treatment. Dopaminergic cell death was accompanied by the appearance of ubiquitin and alpha-synuclein-positive inclusions in the substantia nigra in these rats. Neuronal loss was also observed in the locus ceruleus, raphe nuclei, and dorsal motor nucleus of the vagus, verifying that proteasomal inhibition produces a relevant model of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862581     DOI: 10.1002/ana.20932

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  21 in total

Review 1.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

2.  Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition.

Authors:  Chaoshi Niu; Jiaming Mei; Qi Pan; Xianming Fu
Journal:  Stereotact Funct Neurosurg       Date:  2009-02-18       Impact factor: 1.875

3.  A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo.

Authors:  Shubhangi Prabhudesai; Sharmistha Sinha; Aida Attar; Aswani Kotagiri; Arthur G Fitzmaurice; Rajeswari Lakshmanan; Ravi Lakshmanan; Magdalena I Ivanova; Joseph A Loo; Frank-Gerrit Klärner; Thomas Schrader; Mark Stahl; Gal Bitan; Jeff M Bronstein
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

4.  Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration.

Authors:  Brian N Mathur; M Diana Neely; Melanie Dyllick-Brenzinger; Anurag Tandon; Ariel Y Deutch
Journal:  Brain Res       Date:  2007-07-20       Impact factor: 3.252

5.  Intrastriatal transplantation of GDNF-engineered BMSCs and its neuroprotection in lactacystin-induced Parkinsonian rat model.

Authors:  Jianjun Wu; Wenbo Yu; Yan Chen; Yaru Su; Zhengtong Ding; Huimin Ren; Yuping Jiang; Jian Wang
Journal:  Neurochem Res       Date:  2009-11-06       Impact factor: 3.996

6.  Reciprocal effects of alpha-synuclein overexpression and proteasome inhibition in neuronal cells and tissue.

Authors:  Melanie Dyllick-Brenzinger; Cheryl A D'Souza; Burkhardt Dahlmann; Peter-Michael Kloetzel; Anurag Tandon
Journal:  Neurotox Res       Date:  2009-08-04       Impact factor: 3.911

7.  Pesticides that inhibit the ubiquitin-proteasome system: effect measure modification by genetic variation in SKP1 in Parkinson׳s disease.

Authors:  Shannon L Rhodes; Arthur G Fitzmaurice; Myles Cockburn; Jeff M Bronstein; Janet S Sinsheimer; Beate Ritz
Journal:  Environ Res       Date:  2013-08-27       Impact factor: 6.498

Review 8.  A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease.

Authors:  Casey Cook; Leonard Petrucelli
Journal:  Biochim Biophys Acta       Date:  2009-02-03

9.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

Review 10.  Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?

Authors:  Emma Lane; Stephen Dunnett
Journal:  Psychopharmacology (Berl)       Date:  2007-09-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.